What is Vertex Pharmaceuticals, Inc. Annual Revenue?

Vertex Pharmaceuticals, Inc. Annual Revenue rose 11.66%, in the last year to $11,020.1 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is Vertex Pharmaceuticals, Inc. Annual Net Profit?

Vertex Pharmaceuticals, Inc. Annual Net Profit fell 114.8% in the last year to $535.6 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Vertex Pharmaceuticals, Inc. Price to Earning Ratio?

Vertex Pharmaceuticals, Inc. Price to Earning Ratio is -245.35, which is negative.

What is Vertex Pharmaceuticals, Inc. Stock Price?

Vertex Pharmaceuticals, Inc. Stock Price rose 23.12% and outperformed its sector by 13.22% in the past year.

What is Vertex Pharmaceuticals, Inc. Quarterly Revenue?

Vertex Pharmaceuticals, Inc. Quarterly Revenue rose 15.66% YoY to $2,912 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Vertex Pharmaceuticals, Inc. Quarterly Net profit?

Vertex Pharmaceuticals, Inc. Quarterly Net profit fell 5.76% YoY to $913 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Vertex Pharmaceuticals, Inc. Debt to Equity Ratio?

Vertex Pharmaceuticals, Inc. Debt to Equity Ratio of 0.11 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Vertex Pharmaceuticals, Inc. Return on Equity(ROE)?

Vertex Pharmaceuticals, Inc. Return on Equity(ROE) for the last financial year was -3.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Vertex Pharmaceuticals, Inc. Mutual Fund Holding?

Vertex Pharmaceuticals, Inc. Mutual Fund Holding increased by 0.35% in the last quarter to 93.1.

What is Vertex Pharmaceuticals, Inc. Promoter Share Holding?

Vertex Pharmaceuticals, Inc. Promoter Share Holding increased by 0.03% in the most recent quarter to 0.23%.

What is Vertex Pharmaceuticals, Inc. Interest Coverage Ratio?

Vertex Pharmaceuticals, Inc. Interest Coverage Ratio is 9.12, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Vertex Pharmaceuticals, Inc. Institutional Holding?

Vertex Pharmaceuticals, Inc. Institutional Holding remained the same in the last quarter at 92.81%.

How is the Vertex Pharmaceuticals, Inc. today?

The Vertex Pharmaceuticals, Inc. today is trading in the green, up by 1.70% at 511.74.

How has Vertex Pharmaceuticals, Inc. performed historically?

The Vertex Pharmaceuticals, Inc. is currently trading up 1.70% on an intraday basis in the past week the index rose 1.38%. The index has been up 26.27% in the past quarter and rose 23.12% in the past year. You can view this in the overview section.

Vertex Pharmaceuticals, Inc. XNAS: VRTX

Vertex Pharmaceuticals, Inc. Live Share Price Today, Share Analysis and Chart

Name: Vertex Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Vertex Pharmaceuticals, Inc.
Rating: 1.24529175
Author: Trendlyne DVM scores

Momentum Trap

Download real time

511.74 8.54 (1.70%)

Near 52W High of $519.88

1.2M XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Vertex Pharmaceuticals, Inc. Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	131,409.6
PE TTM Negative PE TTM Unavailable in chosen country	-245.4
PEG TTM High in industry Unavailable in chosen country	2.1
Price to Book High in industry Unavailable in chosen country	8
Institutional holding current Qtr % High in industry Unavailable in chosen country	92.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	15.7
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	11.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-5.8
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-114.8
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	38.2
Operating Profit Margin TTM % High in industry Unavailable in chosen country	39.9
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	19
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-3.2
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-2.4

All financials are in USD Million and price data in USD

Low Financial Strength

16.7 / 100

Expensive Valuation

8.0 / 100

Technically Neutral

58.3 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

497

1Yr Price target downside is -3%

29 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Vertex Pharmaceuticals, Inc. Stock Price Analysis

Day Price Range 1.7% 1 Day return Unavailable in chosen country	511.7 (LTP) 501514 LowHigh
Week Price Range 1.4% 1 Week return Unavailable in chosen country	511.7 (LTP) 501517.2 LowHigh
Month Price Range 5.7% 1 Month return Unavailable in chosen country	511.7 (LTP) 473.5519.7 LowHigh
52 Week Price Range 23.1% 1 Year return Unavailable in chosen country	511.7 (LTP) 378519.9 LowHigh

View full Share Price History

Vertex Pharmaceuticals, Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Vertex Pharmaceuticals, Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-2.1

Avg. Estimate

15.8

Low Estimate

13.5

High Estimate

17.6

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 858.7% in FY25

Consensus Recommendation

34 ANALYST Recommendations

BUY

The consensus recommendation from 34 analysts for Vertex Pharmaceuticals, Inc. is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Vertex Pharmaceuticals, Inc. Stock Analysis

Vertex Pharmaceuticals, Inc. stock analysis with key metrics, changes, and trends.

Vertex Pharmaceuticals, Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$11,020.1 M	11.66%	positive	Annual Revenue rose 11.66%, in the last year to $11,020.1 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$535.6 M	114.8%	negative	Annual Net Profit fell 114.8% in the last year to $535.6 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-245.35	-	negative	Price to Earning Ratio is -245.35, which is negative.
Stock Price	$511.74	23.12%	positive	Stock Price rose 23.12% and outperformed its sector by 13.22% in the past year.
Quarterly Revenue	$2,912 M	15.66%	positive	Quarterly Revenue rose 15.66% YoY to $2,912 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$913 M	5.76%	negative	Quarterly Net profit fell 5.76% YoY to $913 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Debt to Equity Ratio	0.11	-	positive	Debt to Equity Ratio of 0.11 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-3.15 %	-3.15%	negative	Return on Equity(ROE) for the last financial year was -3.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	93.10 %	0.35%	positive	Mutual Fund Holding increased by 0.35% in the last quarter to 93.1.
Promoter Share Holding	0.23 %	0.03%	positive	Promoter Share Holding increased by 0.03% in the most recent quarter to 0.23%.
Interest Coverage Ratio	9.12	-	positive	Interest Coverage Ratio is 9.12, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	92.81 %	0%	neutral	Institutional Holding remained the same in the last quarter at 92.81%.

VIEW LESS

Loading data..

Vertex Pharmaceuticals, Inc. - Company Profile

What does Vertex Pharmaceuticals, Inc. do?

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Gross Remuneration

2024

Gross Remuneration

Year

Vertex Pharmaceuticals, Inc. Live Share Price Today, Share Analysis and Chart

Near 52W High of $519.88

Vertex Pharmaceuticals, Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Vertex Pharmaceuticals, Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Vertex Pharmaceuticals, Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Vertex Pharmaceuticals, Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 858.7% in FY25

Consensus Recommendation

The consensus recommendation from 34 analysts for Vertex Pharmaceuticals, Inc. is BUY

Vertex Pharmaceuticals, Inc. Stock Analysis

Vertex Pharmaceuticals, Inc. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 11.66%, in the last year to $11,020.1 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit fell 114.8% in the last year to $535.6 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -245.35, which is negative.

Stock Price rose 23.12% and outperformed its sector by 13.22% in the past year.

Quarterly Revenue rose 15.66% YoY to $2,912 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit fell 5.76% YoY to $913 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio of 0.11 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -3.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.35% in the last quarter to 93.1.

Promoter Share Holding increased by 0.03% in the most recent quarter to 0.23%.

Interest Coverage Ratio is 9.12, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 92.81%.

Vertex Pharmaceuticals, Inc. - Company Profile

What does Vertex Pharmaceuticals, Inc. do?

Vertex Pharmaceuticals, Inc. Management structure

Mr. Charles F. Wagner, Jr

Executive Vice President and Chief Financial Officer

Mr. Stuart A. Arbuckle

Executive Vice President and Chief Operating Officer

Mr. Duncan J. McKechnie

Senior Vice President and Head, North America Commercial Team

Vertex Pharmaceuticals, Inc. Board of directors

Mr. Terrence C. Kearney

Independent Director

Dr. Jennifer Schneider, M.D.

Independent Director

Mr. Suketu Upadhyay

Independent Director

Mr. Bruce I. Sachs